Daiwa Securities Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Daiwa Securities Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-186	Closed	-$20K	–	1376
2023 Q1	$20K	Buy	186 +17	+10%	+$1.96K	﹤0.01%	1078
2022 Q4	$19K	Buy	169 +23	+16%	+$1.49K	﹤0.01%	1084
2022 Q3	$9K	Hold	146	–	–	﹤0.01%	1136
2022 Q2	$4K	Buy	146 +32	+28%	+$927	﹤0.01%	1193
2022 Q1	$4K	Hold	114	–	–	﹤0.01%	1205
2021 Q4	$5K	Buy	+114	New	+$3.57K	﹤0.01%	1209

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Daiwa Securities Group's RXDX Position: Q2 2023 in Review

Daiwa Securities Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 186 shares — an estimated $20K sold.

Daiwa Securities Group first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $20K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Daiwa Securities Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Daiwa Securities Group sold 186 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $20K.
Daiwa Securities Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Daiwa Securities Group's Prometheus Biosciences, Inc. Common Stock position peaked at $20K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Daiwa Securities Group's 13F filing for Q2 2023, filed 31 Jul 2023.